Abstract: The present disclosure provides methods of treating subjects having Alzheimer's Disease, and methods of identifying subjects having an increased risk of developing Alzheimer's Disease.

Abstract: The present disclosure provides methods of treating subjects having a lung disease such as a fibrotic lung disease, pulmonary fibrosis, interstitial lung disease, chronic obstructive pulmonary disease (COPD), or asthma, or at risk of developing a lung disease, and methods of identifying subjects having an increased risk of developing a lung disease.

Abstract: The present disclosure provides methods of treating subjects having an inflammatory disease, and methods of identifying subjects having an increased risk of developing an inflammatory disease.

Abstract: The present disclosure provides methods of treating subjects having psoriasis, and methods of identifying subjects having an increased risk of developing psoriasis.

Abstract: The present disclosure provides methods of treating a subject having asthma or at risk of developing asthma, and methods of identifying subjects having an increased risk of developing asthma.

Abstract: The invention provides a method for diagnosing Inflammatory Bowel Diseases, using genetic markers that are implicated in severe, early-onset Crohn's Disease (CD). The invention also provides coding sequence mutations in the OCTN1 gene that significantly reduces its ability to transport the organic cation carnitine. The invention further provides mutations in the promoter region of OCTN2 (that downregulates both basal transcription and transcription induced either by heat shock or arachidonic acid. This transcription difference is apparently due to the disruption of a binding site for heat shock transcription factor 1 (HSF 1). A haplotype of two mutations is found in Crohn's Disease (CD) patients. Together, these mutations reduce cellular ability to respond to metabolic stress in inflamed tissue and may further be involved in the clearance of toxic substances from cells.

Abstract: The invention provides a method for diagnosing Inflammatory Bowel Diseases, using genetic markers that are implicated in severe, early-onset Crohn's Disease (CD). The invention also provides coding sequence mutations in the OCTN1 gene that significantly reduces its ability to transport the organic cation carnitine. The invention further provides mutations in the promoter region of OCTN2 (that downregulates both basal transcription and transcription induced either by heat shock or arachidonic acid. This transcription difference is apparently due to the disruption of a binding site for heat shock transcription factor 1 (HSF1). A haplotype of two mutations is found in Crohn's Disease (CD) patients. Together, these mutations reduce cellular ability to respond to metabolic stress in inflamed tissue and may further be involved in the clearance of toxic substances from cells.

Abstract: A method of assaying for glycosyltransferase activity in a sample. In a first step, a sample is reacted with a first sugar donor and an acceptor substrate to produce a transferase product. The first sugar donor and acceptor substrate are selected such that the sugar from the first sugar donor is capable of being transferred to the acceptor substrate in the presence of the glycosyltransferase to be assayed. In a second step, the transferase product is reacted with a second sugar donor having a sugar which is labelled with a labelling agent and an enzyme which is capable of transferring the sugar from the second sugar donor to the transferase product to produce a labelled transferase product and which has a higher affinity for the glycosyltransferase product compared to the affinity of the glycosyltransferase for the acceptor substrate. The labelling agent activity of the labelled transferase product or unreacted second sugar donor is assayed to determine transferase activity in the sample.